Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Effic

In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% Meets protocol primary objective of assessing the primary...

Related Keywords

United States , America , Davidp Luci , Robertj Deluccia , Kevin Garey , Stuart Johnson , Nasdaq , Peggy Lillis Foundation , Trial Oversight Committee , Data Monitoring Committee , Acurx Pharmaceuticals , C Diff Foundation , Prnewswire Acurx Pharmaceuticals Inc , University Of Houston College Pharmacy , Company Scientific Advisory Board , Drug Administration , Us Centers For Disease , Company Ph , Loyola University Infectious Disease , Acurx Pharmaceuticals Inc , Society Or Healthcare Epidemiology Of America , Exchange Commission On Form , Infectious Diseases Society Of America , Cdiff Foundation , Clinical Cure , Serious Adverse , Sustained Clinical Cure , Extended Clinical Cure , Infectious Disease Product , Independent Data Monitoring Committee , Modified Intent , Treat Population , Per Protocol Population , Prescribing Information , Loyola University , Infectious Disease , Acurx Scientific Advisory Board , Houston College , Principal Investigator , Executive Chairman , Chief Executive Officer , Awareness Month , Disease Control , Clinical Trials , Environmental Safety , Lillis Foundation , Ibezapolstat Phase , Scientific Advisory Board , Fast Track Designated , Gram Positive Selective Spectrum , Qualified Infectious Disease Product , Generating New Antibiotic Incentives Now , Clinical Practice Guidelines , Infectious Diseases Society , Healthcare Epidemiology , New England Journal , New England , Bile Acid , Private Securities Litigation Reform Act , Exchange Commission , Nc ,